ChemT Raises $5 Mn in Round led by Wavemaker Ventures

ChemT combines machine learning with real laboratory testing. It says this can help manufacturers of biologic medicines and cell therapies develop products faster and achieve better production results.

Producing biologic medicines on a large scale is still one of the biggest challenges in the biotech industry. Companies often face complex manufacturing processes that are difficult to manage and optimize.

Drug makers and contract manufacturing companies (CDMOs) frequently deal with long development timelines, inconsistent production results, and lower yields. Many processes that work well in small pilot tests can also face problems when scaled up for commercial production.

“Within roughly a year and half of launch, we’ve built commercial partnerships with more than 40 pharmaceutical, biotech, and CDMO companies across the globe,” ChemT co‑founder and CEO Jie Sun said. “The future of bio-manufacturing will not be won by automation alone; it will require intelligence.”

“Bio-manufacturing has long been constrained by structural bottlenecks… ChemT addresses this through precision small molecules that modulate cellular behaviour, giving manufacturers a new lever for faster, cheaper, and higher‑yield production with consistent quality,” said Paul Santos, co‑founder and managing partner at Wavemaker Partners. His comment underlines investor appetite for teams that combine computational capability, wet‑lab credibility and commercial channels, a combination that can be scarce among early life‑science startups.

Founded in 2024 by Dr. Ling Wu and Jie Sun, ChemT Biotechnology is developing new technology to improve the manufacturing of biologic medicines. Founded by experts in biopharma, artificial intelligence, and entrepreneurship, the company uses AI to design small molecules that help make production more efficient and reliable.

Its main product, an AI-designed small molecule compound, has shown the ability to increase production yields by 5 to 10 times while also improving product quality. The technology has already demonstrated positive results in both laboratory and animal studies.

Read Also- Recykal Secures $23 Million to Scale Global Waste Management Operations